

# Robert Weinstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9046251/publications.pdf>

Version: 2024-02-01

42  
papers

1,715  
citations

567281

15  
h-index

315739

38  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1256  
citing authors

#	ARTICLE	IF	CITATIONS
1	Writing scientific case reports for top-line journals. Journal of Clinical Apheresis, 2021, 36, 465-469.	1.3	2
2	Surviving peer review. Journal of Clinical Apheresis, 2020, 35, 469-476.	1.3	1
3	How to write a manuscript for peer review. Journal of Clinical Apheresis, 2020, 35, 358-366.	1.3	4
4	Optimization of infusional calcium gluconate for prevention of hypocalcemic reactions during therapeutic plasma exchange. Journal of Clinical Apheresis, 2019, 34, 656-660.	1.3	2
5	Performance characteristics of the PowerFlow apheresis port: Early experience. Journal of Clinical Apheresis, 2019, 34, 661-665.	1.3	3
6	A liquid calcium+vitamin D <sub>3</sub> supplement is effective prophylaxis against hypocalcemic toxicity during apheresis platelet donation. Journal of Clinical Apheresis, 2018, 33, 60-64.	1.3	6
7	Automated red blood cell exchange in preparation for filgrastim mobilization of autologous peripheral blood hematopoietic progenitor cells in a patient with sickle cell anemia. Journal of Clinical Apheresis, 2018, 33, 431-435.	1.3	2
8	Dietary citrate and plasma ionized calcium: Implications for platelet donors. Journal of Clinical Apheresis, 2018, 33, 222-225.	1.3	3
9	Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods. Journal of Clinical Apheresis, 2018, 33, 600-603.	1.3	7
10	Therapeutic plasma exchange performed in tandem with hemodialysis without supplemental calcium in the apheresis circuit. Journal of Clinical Apheresis, 2017, 32, 154-157.	1.3	4
11	Therapeutic apheresis using a mononuclear cell program to lower the microfilaria burden of a 23-year-old African woman with loiasis. Journal of Clinical Apheresis, 2017, 32, 200-202.	1.3	3
12	Therapeutic phlebotomy and specialized hemapheresis. , 2016, , 407-417.		0
13	Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia. Journal of Clinical Apheresis, 2016, 31, 393-397.	1.3	8
14	Therapeutic leukocytapheresis for improvement in respiratory function in a woman with hyperleukocytosis and mantle cell lymphoma with a circulating small lymphocyte phenotype. Journal of Clinical Apheresis, 2016, 31, 398-402.	1.3	2
15	Prospective surveillance of $D^{\wedge}n$ recipients of $D^{+}$ apheresis platelets: alloimmunization against $D$ is not detected. Transfusion, 2015, 55, 1327-1330.	1.6	21
16	Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity. Journal of Clinical Apheresis, 2015, 30, 367-370.	1.3	8
17	Safety and efficacy of autologous hemopoietic progenitor cell collection in tandem with hemodialysis in multiple myeloma with myeloma cast nephropathy. Journal of Clinical Apheresis, 2014, 29, 83-89.	1.3	7
18	Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME). Transfusion, 2014, 54, 1751-1755.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Evidence-Based Review of Therapeutic Plasma Exchange in Neurological Disorders. <i>Seminars in Dialysis</i> , 2012, 25, 132-139.	1.3	9
20	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. <i>Journal of Clinical Apheresis</i> , 2010, 25, 83-177.	1.3	441
21	Therapeutic apheresis in neurological disorders: A survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , 2008, 23, 196-201.	1.3	14
22	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. <i>Journal of Clinical Apheresis</i> , 2007, 22, 106-175.	1.3	308
23	Therapeutic plasma exchange performed in tandem with hemodialysis for patients with M-protein disorders. <i>Journal of Clinical Apheresis</i> , 2006, 21, 100-104.	1.3	27
24	Long-term therapeutic plasma exchange in the outpatient setting using an implantable central venous access device. <i>Journal of Clinical Apheresis</i> , 2004, 19, 180-184.	1.3	11
25	Prospective investigation of a subcutaneous, implantable central venous access device for therapeutic plasma exchange in adults with neurological disorders. <i>Journal of Clinical Apheresis</i> , 2002, 17, 1-6.	1.3	11
26	Transfusion-related acute lung injury after the infusion of IVIG. <i>Transfusion</i> , 2001, 41, 264-268.	1.6	132
27	Regional editorial: IT programmes and policies in the Asia-Pacific region. <i>Journal of Computer Assisted Learning</i> , 2001, 17, 1-3.	5.1	8
28	Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. <i>Muscle and Nerve</i> , 2001, 24, 778-786.	2.2	80
29	Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , 2001, 16, 210-211.	1.3	50
30	Therapeutic apheresis in neurological disorders. <i>Journal of Clinical Apheresis</i> , 2000, 15, 74-128.	1.3	66
31	Pentastarch as partial replacement fluid for therapeutic plasma exchange: Effect on plasma proteins, adverse events during treatment, and serum ionized calcium. <i>Journal of Clinical Apheresis</i> , 1999, 14, 114-121.	1.3	34
32	Response of patients with IgM and IgA-associated peripheral polyneuropathies to "off-line" immunoadsorption treatment using the ProSORBA <sup>®</sup> 1/2 protein A column. , 1999, 14, 159-162.		6
33	Phytanic acid storage disease (Refsum's disease): Clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management. , 1999, 14, 181-184.		53
34	How to write an abstract and present it at the annual meeting. , 1999, 14, 195-199.		7
35	Treatment of high-risk, refractory acquired methemoglobinemia with automated red blood cell exchange. <i>Journal of Clinical Apheresis</i> , 1998, 13, 28-31.	1.3	43
36	Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: Prospective observations of an emerging syndrome. <i>Journal of Clinical Apheresis</i> , 1997, 12, 159-164.	1.3	35

#	ARTICLE	IF	CITATIONS
37	Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: Prospective observations of an emerging syndrome. <i>Journal of Clinical Apheresis</i> , 1997, 12, 159-164.	1.3	1
38	Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. <i>Journal of Clinical Apheresis</i> , 1996, 11, 204-210.	1.3	79
39	Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute guillain-barré syndrome?. <i>Journal of Clinical Apheresis</i> , 1995, 10, 150-157.	1.3	12
40	Complications of therapeutic plasma exchange: A recent assessment. <i>Journal of Clinical Apheresis</i> , 1994, 9, 1-5.	1.3	123
41	Successful management of paraprotein-associated peripheral polyneuropathies by immunoadsorption of plasma with staphylococcal protein A. <i>Journal of Clinical Apheresis</i> , 1993, 8, 72-77.	1.3	14
42	Growth factor responses of human arterial endothelial cells in vitro. <i>In Vitro Cellular &amp; Developmental Biology</i> , 1986, 22, 549-556.	1.0	24